Compare SCD & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | KALA |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.2M | 319.6M |
| IPO Year | N/A | 2017 |
| Metric | SCD | KALA |
|---|---|---|
| Price | $14.84 | $0.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 37.5K | ★ 6.5M |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | ★ 41.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.35 | $0.23 |
| 52 Week High | $16.89 | $20.58 |
| Indicator | SCD | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 29.14 | 31.56 |
| Support Level | $14.65 | $0.23 |
| Resistance Level | $15.11 | $0.72 |
| Average True Range (ATR) | 0.33 | 0.04 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 0.79 | 7.86 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.